Nausea and vomiting are considered by patients chemotheraplc Side effects so disabling to inspire the refusal of treatment. In our ambulatory we use standard patterns of antiemetic therapy relationed to the emetogenic effects of chemotherapic protocols. That ensures the management of protocols by paramedical staff which, helped by a more careful rating of quality of life with psychological tests as SCI and FLIC, uses the antiemetics in a good way. From September 1992 to February 1994 we evaluated the episodes of nausea and vomiting in three groups of patients. GROUP A: 5FU and Folinic Acid treatment; antiemetic Metoclopramide or Alizapride. GROUP B: CMF treatment, randomization between Anti-H3 and Metoclopramide. GROUP C: Cisplatin treatment; antiemetic: Anti-H3. Results GROUP A: In a total of 78 cycles of chemotherapy we observed 50% events of nausea grade 1–2 WHO and 10% events of vomit which didn’t last more than 48 hours. GROUP B: In a total of 78 cycles we observed 78% episodes of nausea grade 2–3 WHO in the subgroup Anti-H3 and 92% episodes of nausea grade 2–3 WHO, with vomiting not lasting more than 48 hours, in the subgroup Metoclopramide. GROUP C: In a total of 60 cycles we observed 60% episodes of nausea grade 3–4 WHO with 47% episodes of vomiting lasting more than 72 hours. Conclusions our results underline a control of emesis slightly lower than literature data with utilization of Anti-H3. The antiemetic management employed by this nurse-team makes the support therapy easier.